クリグルファーマ株式会社

development

Research & Development -Background-

The mission of our company is to provide a novel medical treatment for patients who suffer from cancer and incurable diseases by research and development of HGF (hepatocyte growth factor) and its intramolecular fragment NK4. Our goal is to provide original medicines for global healthcare based on the innovative drug research conducted in Japan.

Project Drug Substance Target Disease Development Stage Alliance
HGF Recombinant protein Acute spinal cord injury Phase I/II completed in Japan To be determined
Amyotrophic lateral sclerosis (ALS) Investigator-initiated Phase II ongoing in Japan To be determined
Acute kidney injury Phase I completed in the US To be determined
Vocal fold scar Investigator-initiated Phase I/II completed in Japan To be determined

The Strengths of HGF


HGF, hepatocyte growth factor, was isolated as a mitogenic protein for hepatocytes and genetically cloned for the first time by Professor Toshikazu Nakamura of Osaka University. From subsequent research, it was found that HGF has an extremely potent regenerative healing ability in regard to not only liver cells, but a wide variety of cells and organs. In particular, the antifibrotic action of HGF is an action not seen with other growth factors and so it has the potential to become a revolutionary therapeutic agent for intractable fibrotic diseases with no method of treatment.

About HGF